Pediatric community-acquired pneumonia treated with a three-day course of tebipenem pivoxil.

Abstract

We evaluated the efficacy and safety of a 3-day treatment regimen of tebipenem pivoxil for pediatric community-acquired pneumonia. Tebipenem pivoxil was administered to 49 patients, and its effectiveness was evaluated in 36 patients 2-4 days after initiation of treatment. Thirty-two patients were cured 7-15 days after initiation of treatment. Body temperature was significantly lower on the day following initial administration (median 38.8 to 37.0 °C, n = 33). Leukocyte counts and C-reactive protein levels were significantly reduced by Day 2-4 of treatment (median 16,100 to 7800 white blood cells/μL, and 5.6 to 1.5 mg/dL, respectively; n = 28). Six of the 49 patients had mild diarrhea. Thus, we concluded that 3-day treatment with tebipenem pivoxil was safe and efficacious for treating pediatric community-acquired pneumonia.

• Authors: Hiroshi Sakata, Haruo Kuroki, Kazunobu Ouchi, Takeshi Tajima, Satoshi Iwata, World's First Oral Carbapenem Study Group
• Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (J Infect Chemother) Vol. 23 Issue 5 Pg. 307-311 (May 2017) ISSN: 1437-7780 [Electronic] Netherlands
• PMID: 28238680 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Chemical References

• Anti-Bacterial Agents
• Carbapenems
• C-Reactive Protein
• tebipenem

Topics

• Adolescent
• Anti-Bacterial Agents (therapeutic use)
• C-Reactive Protein (metabolism)
• Carbapenems (therapeutic use)
• Child
• Child, Preschool
• Community-Acquired Infections (drug therapy, metabolism, microbiology)
• Female
• Humans
• Infant
• Male
• Pneumonia (drug therapy, metabolism, microbiology)